Breakouts and Breakdowns: Harnessing the Potential of Small-Caps (APVO, FMST, MYMD, THAR, NIVF)

In the world of investing in stocks, uncovering concealed potentials within small-cap enterprises can result in significant profits. These underestimated businesses thrive because of the complex mechanisms of catalysts, driving them towards success. Today, our attention shifts to five small-cap stocks, examining the factors driving their expansion and sparking investor enthusiasm.

Aptevo Therapeutics Inc. (NASDAQ: APVO) - Aptevo Therapeutics Inc. saw its stock rise by 5% to $3.63 by the end of last week's trading session. The company recently announced its focus on advancing its leading clinical blood cancer candidate, APVO436. This involves conducting clinical trials to evaluate its therapeutic potential, both independently and in conjunction with other treatments. Encouraging results from Phase 1 studies have led to plans for a Phase 1b/2 trial in the first half of 2024, targeting frontline AML patients. This trial will assess the safety and efficacy of APVO436 in combination with Venetoclax and Azacitidine. We'll monitor closely for a potential break above the $3.95 resistance level and for sustained support around the $3.30 mark while awaiting further company updates. Additionally, it's important to note that the company filed an S-1 last month.

--

Foremost Lithium Resource & Technology Ltd. (NASDAQ: FMST) - Foremost Lithium Resource & Technology Ltd. saw its stock climb by 9% to $3.05 at the close of last week's trading session. The company provided an update last month on drilling progress at the Zoro Lithium Property in Manitoba's Snow Lake region. Notably, Foremost reported its widest drill intercept yet at Dyke 1, spanning 32.53 meters of spodumene-bearing pegmatite. Jason Barnard, President and CEO of Foremost Lithium, emphasized the significance of this find for potential resource expansion. The company's focus remains on building resources to the south of Dyke 1, an area showing promise with confirmed spodumene pegmatite. Core processing continues on-site, with samples sent to SGS Canada's laboratory in Burnaby for analysis. Results are pending and expected to be released in batches in the coming weeks. As we await further updates, attention is drawn to the $3.15 resistance level and potential support around $2.85.

--

MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) - MyMD Pharmaceuticals, Inc. closed last week's trading session with a decrease of over 3% at $2.10. This month, the company announced in its annual report the completion of enrollment in the fourth and final cohort of patients for the Phase 2 Aging and Sarcopenia Study. This study, titled "A Double-Blind, Placebo-controlled, Randomized Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD-1 in The Treatment of Participants Aged 65 Years or Older with Chronic Inflammation Associated with Sarcopenia/Frailty," is progressing towards submission to the FDA in the beginning of the second quarter of 2024. Exploratory analysis highlights sTNFR1 as the most sensitive biomarker for Sarcopenia patients aged 65-75 years old. PK analysis shows consistency in PK/PD strategy with biomarker measurements 2-4 hours post-dose. The study reported no serious adverse events or dropouts due to adverse events, and no clinically significant cardiovascular, ECG issues, or neurotoxicity were observed in any patients. We'll monitor for a breakout above the $2.25 resistance level and also keep an eye on potential support levels for consolidation as we await further updates from the company.

--

Tharimmune Inc. (NASDAQ: THAR) - Tharimmune Inc. saw a decline of over 2% in its company shares at the close of last week's trading session, ending at $0.44. In February, the company announced the successful completion of its Phase 1 clinical trial involving TH104. TH104 is a proprietary transmucosal buccal film containing the approved active compound nalmefene, designed to adhere easily inside the mouth on the cheek and biodegrade within minutes. This innovative formulation aims to bypass the liver's initial metabolic process, potentially making it a promising candidate for various liver-related and other pruritogenic inflammatory conditions. With a dual mechanism of action targeting mu and kappa opioid receptors, TH104 underwent testing with twenty normal healthy volunteers, with 19 completing the study. The primary objective was to evaluate TH104's absolute bioavailability and assess its safety and tolerability. Currently, Phase 1 pharmacokinetic analysis is ongoing, and the company anticipates releasing topline results and full data in the second quarter of 2024. While awaiting future company updates, we'll monitor closely for a potential breakout above the $0.49 resistance level. Additionally, it's important to note that the company has a scheduled vote for a reverse split in May.

--

NewGenIvf Group Limited (NASDAQ: NIVF) - NewGenIvf Group Limited's company shares closed last week's trading session with a 33% decrease, settling at $1.00. The company recently announced its completion of a business combination with A SPAC I Acquisition Corp. (NASDAQ: ASCA), forming the combined entity "NewGenIvf Group Limited" ("NewGenIvf Group"). The newly merged company's shares and warrants are expected to commence trading on the Nasdaq Capital Market under the tickers "NIVF". Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, expressed excitement about the Nasdaq debut and highlighted the increasing demand for fertility services in Asia. He emphasized the company's readiness to capitalize on this growing market and its commitment to providing comprehensive fertility solutions. As we await company updates, we'll monitor support around $1.00, considering recent increased volume in after-hours trading on Friday. Additionally, we'll be attentive to any potential resistance breakthrough at the $1.20 mark.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.